Literature DB >> 7790858

Demonstration of kappa 3-opioid receptors in the SH-SY5Y human neuroblastoma cell line.

J Cheng1, K M Standifer, P R Tublin, W Su, G W Pasternak.   

Abstract

In addition to the mu- and delta-opioid receptors previously reported, the SH-SY5Y human neuroblastoma cell line has high levels of kappa 3 receptors, accounting for 40% of total opioid binding, as measured with [3H]-diprenorphine binding. Competition studies reveal binding profiles for all three receptor classes that are similar to those observed in brain membranes. Differentiation with retinoic acid increases the levels of opioid receptor binding in the cell line, with the largest elevations in kappa 3 binding. Fully 75% of the increased binding corresponds to kappa 3 sites, which represent 50% of total opioid receptor binding in differentiated cells. Morphine inhibits forskolin-stimulated cyclic AMP accumulation, and this effect is readily blocked by the mu antagonist D-Phe-Cys-Tyr-D-Trp-Arg-Thr-Pen-Thr-NH2 (CTAP). Naloxone benzoylhydrazone, a kappa 3 agonist, inhibits forskolin-stimulated cyclic AMP accumulation more potently than morphine and is not reversed by CTAP. These studies indicate that SH-SY5Y cells contain high levels of functional kappa 3 receptors.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7790858     DOI: 10.1046/j.1471-4159.1995.65010170.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  9 in total

1.  Nociceptin/Orphanin FQ Inhibits the Survival and Axon Growth of Midbrain Dopaminergic Neurons Through a p38-MAPK Dependent Mechanism.

Authors:  Louise M Collins; Giorgia Dal Bo; Mariangela Calcagno; Jimena Monzón-Sandoval; Aideen M Sullivan; Humberto Gutierrez; Michele Morari; Gerard W O'Keeffe
Journal:  Mol Neurobiol       Date:  2015-12-21       Impact factor: 5.590

2.  The effect of nociceptin on Ca2+ channel current and intracellular Ca2+ in the SH-SY5Y human neuroblastoma cell line.

Authors:  M Connor; A Yeo; G Henderson
Journal:  Br J Pharmacol       Date:  1996-05       Impact factor: 8.739

3.  [Expression und function of the ORL-1 receptor on human leukocytes].

Authors:  C Krüger; L Köthe; A Struppert; C Pietruck; A Simm; S Grond
Journal:  Schmerz       Date:  2006-11       Impact factor: 1.107

4.  Opioid-induced down-regulation of RGS4: role of ubiquitination and implications for receptor cross-talk.

Authors:  Qin Wang; John R Traynor
Journal:  J Biol Chem       Date:  2011-01-05       Impact factor: 5.157

5.  Agonist activity of naloxone benzoylhydrazone at recombinant and native opioid receptors.

Authors:  Maria C Olianas; Danilo Concas; Pierluigi Onali
Journal:  Br J Pharmacol       Date:  2006-02       Impact factor: 8.739

Review 6.  The delta opioid receptor tool box.

Authors:  Ana Vicente-Sanchez; Laura Segura; Amynah A Pradhan
Journal:  Neuroscience       Date:  2016-06-24       Impact factor: 3.590

7.  G protein activation and cyclic AMP modulation by naloxone benzoylhydrazone in distinct layers of rat olfactory bulb.

Authors:  Pierluigi Onali; Maria C Olianas
Journal:  Br J Pharmacol       Date:  2004-09-27       Impact factor: 8.739

8.  Tyr-c[D-Orn-Tyr(Bzl)-Pro-Gly]: a novel antiproliferative acting somatostatin receptor agonist with mu-opioid receptor-sensitizing properties.

Authors:  Jörg Stirnweiss; Bianka Hartrodt; Gisela Greksch; Uta Stürzebecher; Frank-D Böhmer; Klaus Neubert; Claus Liebmann
Journal:  Br J Pharmacol       Date:  2003-08-04       Impact factor: 8.739

Review 9.  Researching glutamate - induced cytotoxicity in different cell lines: a comparative/collective analysis/study.

Authors:  Aristeidis A Kritis; Eleni G Stamoula; Krystallenia A Paniskaki; Theofanis D Vavilis
Journal:  Front Cell Neurosci       Date:  2015-03-17       Impact factor: 5.505

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.